Navigation Links
NY Gov. Paterson renews commitment to stem cell research in visit to Cold Spring Harbor Laboratory
Date:10/9/2009

Cold Spring Harbor, NY -- On a visit to Cold Spring Harbor Laboratory (CSHL) Thursday afternoon, New York Governor David A. Paterson pledged his continuing support for stem cell research after receiving a briefing from a panel of Long Island scientists engaged in projects involving stem cells.

The Governor recalled that in January 2005, in his first press conference after being elected New York's lieutenant governor, he publicly committed himself to the advance of stem cell research in New York; it would be one of his top four priorities, he stated at that time. The others were the development of alternative energy sources, the problem of domestic violence, and the promotion of business enterprises run by women and members of minority groups. His commitment to stem cell research and the other priorities, he affirmed yesterday, have not changed in the 17 months since he became governor.

"We have a lot of plans that have undergone reprocessing because of the continuing financial and fiscal crises, but we're continuing to fund stem cell research at the state level at a rate of between $50 million and $60 million per year," Paterson said. The Governor has spearheaded an effort to commit $600 million in state funds over the next decade to advance stem cell science within the state. Since 2008, over $165 million has been allocated by the Empire State Stem Cell Board.

The Governor's visit to CSHL provided an opportunity for him to receive briefings from CSHL President Bruce Stillman, Ph.D., and four faculty scientists: Drs. Linda Van Aelst, Grigori Enikolopov and Marja Timmermans, and Clinical Fellow Johannes Zuber, M.D.

Gov. Paterson, who was joined by State Health Commissioner Richard F. Daines, M.D., who chairs the Empire State Stem Cell Board, and by Assemblyman Charles D. Levine of Glen Cove, also heard from Dr. Samuel Stanley, President of Stony Brook University and Dr. Ira S. Cohen, a Stony Brook cardiologist and re
'/>"/>

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
2. NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards
3. Business, scientific, higher education groups laud President Obamas commitment to science
4. Research shows skeleton to be endocrine organ
5. Newly created cancer stem cells could aid breast cancer research
6. Dominant cholesterol-metabolism ideas challenged by new research
7. Researchers identify proteins involved in new neurodegenerative syndrome
8. Texas researchers and educators head for Antarctica
9. MGH researchers describe new way to identify, evolve novel enzymes
10. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
11. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... body's natural immune responses could be a target of future cancer ... of Medicine of the University of Southern California. , The ... of Pathology, is the first to identify how EphB4 ?a protein ... important aspect of this study is that ?if we turn the ...
... uncovered a new cellular secret that may explain how ... cancers that makes treatment especially difficult. If the mechanism ... can be understood well enough to manipulate it, new ... metastatic cancers. , Significance of the Mayo Clinic ...
... potentially powerful new therapy for treating diabetes, peripheral vascular ... and into animals by demonstrating it restores nerve and ... particularly important implications for the estimated 21 million Americans ... blood vessels. , The therapy involves netrins, a family ...
Cached Biology News:USC researchers investigate protein that protects tumors 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 3Proteins spur diabetic mice models to grow blood vessels, nerves 2
(Date:7/27/2015)... July 27, 2015 According to the ... (Home-brew Media, Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, Drug ... Europe , Asia-Pacific , Rest ... global biopreservation media market was valued at $247.7 million in ... by 2019, at a CAGR of 18.2% between 2014 and ...
(Date:7/27/2015)... , July 27, 2015 IDEXX Laboratories, Inc. ... 8,000 clinics have submitted over 100,000 specimens to IDEXX ... just the first 10 days since the breakthrough kidney ... (CKD) is a leading cause of suffering and death ... specimens are consistent with generally accepted kidney disease prevalence ...
(Date:7/25/2015)... ... , ... Technology leader Anton Paar offers the Abbemat ... temperature of the measuring prism. This is required to achieve the most precise ... key requirements. It is likely that no refractometer manufacturers on the market can ...
(Date:7/24/2015)... -- Equity Research Institute has initiated coverage ... PDLI ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... (NASDAQ: NWBO ), and Acorda Therapeutics Inc. (NASDAQ: ... can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI On Thursday, ... down 0.49%, the Dow Jones Industrial Average declined 0.67%, ...
Breaking Biology Technology:Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5It’s T-Time for Refractometers: On-site Temperature Check Now Available 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... , Revamilast is a PDE4 inhibitor, under development for ... successfully completed pre-clinical trials and Phase I studies , Phase ... UK , , Glenmark has initiated global  Phase IIb ... unmet medical need as globally they are over 300 million Asthma ...
... QinetiQ North America today announced the results of its ... experiment, which studied the effects of microgravity on host ... results of this experiment showed both the plants and ... (Biological Research In a Canister) homes on the shuttle. ...
... Bharat Renewable Energy Ltd (BREL) , a joint-venture of ... a program with SG Biofuels (SGB) to ... production of biodiesel in India. The program,s ... high performing hybrid varieties of Jatropha adapted to unique ...
Cached Biology Technology:Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 2Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 3Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 4QinetiQ North America Gains New Insights into Plant Growth and Sustainable Life Support on Final Shuttle Flight 2Bharat Renewable Energy Forms Alliance With SG Biofuels to Deploy Jatropha Hybrids for Biodiesel in India 2